News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astellas Pharma Inc. (YPH.BE), Evec Team Up for Antibody Pact Worth Up to $176.8 Million


9/6/2011 8:18:58 AM

Astellas is set to get worldwide manufacturing, development and commercialization rights for Evec's fully-human antibodies targeting infectious diseases. Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases. Astellas will pay a sum of JPY0.6bn as an upfront payment to Evec, under the license agreement.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES